| DC23873 |
BMS-986115 |
BMS-986115 is an orally bioavailable, γ-secretase and pan-Notch inhibitor with potential antineoplastic activity. |
|
| DC23459 |
BMS-986118 |
BMS-986118 is a potent and selective GPR40 agonist with EC50 of 70 and 63 nM for hGPR40 and mGPR40, shows no PPARγ activity (EC50>47 uM). |
|
| DC26073 |
BMS-986122
Featured
|
BMS-986122 is a potent positive allosteric modulator of μ-opioid receptor, significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells.. |
|
| DC23609 |
BMS-986163 |
BMS-986163 is a water-soluble phosphate prodrug of BMS-986169, which is a novel GluN2B negative allosteric modulator (Ki=4.0 nM).. |
|
| DC12174 |
Deucravacitinib(BMS986165)
Featured
|
BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2). |
|
| DC23532 |
BMS-986166
Featured
|
BMS-986166 (BMS986166) is a potent, selective S1P receptor modulator for the treatment of ulcerative colitis.. |
|
| DC23639 |
BMS-986169 |
BMS-986169 is a novel GluN2B negative allosteric modulator, demonstrates high binding affinity for the GluN2B allosteric site (Ki=4.0 nM) and selective inhibition of GluN2B receptor function (IC50=24 nM) in cells. |
|
| DC23460 |
BMS986187
Featured
|
BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor.. |
|
| DC22036 |
BMT-046091 |
BMT-046091 (BMT046091) is a potent and selective AAK1 inhibitor with IC50 of 2.8 nM. |
|
| DC23998 |
BMX-IN-1
Featured
|
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity. |
|
| DC23754 |
BNC-1 |
BNC-1 is a small molecule modulator of Amyloid pathology by promoting phosphorylation and activation of Elk-1, a transcriptional repressor of presenilin-1 but not presenilin-2. |
|
| DC7773 |
BNC-105
Featured
|
BNC105 is a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. |
|
| DC23262 |
BNM-III-170 |
BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo. |
|
| DC23243 |
BNM-III-170 trifluoroacetate |
BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo. |
|
| DC20823 |
BNS-22 |
BNS-22 is a small-molecule inhibitor of DNA topoisomerase II, inhibits kinetoplast DNA decatenation that is mediated by human TOP2α and TOP2β in vitro with IC50 of 2.8 and 0.42 uM, respectively. |
|
| DC22037 |
Bobcat339
Featured
|
Bobcat339 (Bobcat 339) is a novel cytosine-based TET enzyme inhibitor with IC50 of 33 uM (TET1) and 73 uM (TET2), but not DNMT3a, does not inhibit the DNA methyltransferase DNMT3a. |
|
| DC23218 |
BOC-D-FMK
Featured
|
BOC-D-FMK is a cell-permeable, irreversible, broad spectrum caspase inhibitor, inhibits apoptosis stimulated by TNF-α with IC50 of 39 uM. |
|
| DC20034 |
Boc-MLF TFA |
Boc-MLF (TFA) is a peptide, used as a specific formyl peptide receptor (FPR) antagonist, also inhibits the signaling through formyl peptide receptor like 1 (FPRL1) at higher concentrations. |
|
| DC8073 |
Bohemine
Featured
|
Bohemine is a synthetic, cell-permeable, cyclin-dependent kinase inhibitor. |
|
| DC21869 |
Borussertib
Featured
|
Borussertib is a potent, first-in-class, covalent-allosteric AKT inhibitor. |
|
| DC12405 |
BOS172722
Featured
|
BOS172722 (BOS-172722) is a potent, selective MPS1 kinase inhibitor with biochemical IC50 of 11 nM, 100-fold selectivity over CDK2. |
|
| DC5164 |
Bosutinib (SKI-606)
Featured
|
Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. |
|
| DC23896 |
Box5 |
Box5 is a Wnt5a-derived N-butyloxycarbonyl hexapeptide (t-Boc-Met-Asp-Gly-Cys-Glu-Leu), acts as an Wnt5a antagonist. |
|
| DC20322 |
BPIPP |
BPIPP is an inhibitor of GC-C (guanylyl cyclase type C) that inhibits stimulation of guanylyl cyclase and adenylyl cyclase, suppresses cGMP accumulation in a variety of cell lines (IC50=3.4-11.2 uM). |
|
| DC12608 |
BPN14770
Featured
|
BPN14770 (BPN-14770) is an allosteric inhibitor of phosphodiesterase 4D (PDE4D) with IC50 of 7.8 and 7.4 nM for human PDE4D7 and PDE4D3 respectively, displays 16-fold less potent against monomeric form of PDE4D lacking the UCR1 dimerization domain (PDE4D2 |
|
| DC23884 |
BPN-15606 |
BPN-15606 (BPN15606) is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 by SHSY5Y neuroblastoma cells with IC50 of 7 nM. |
|
| DC8294 |
BPR1J-097
Featured
|
BPR1J-097 is a novel small molecule FLT-3 inhibitor(IC50=11±7 nM) with promising in vivo anti-tumour activities; inhibits FLT-3 D835Y with an IC50 of 3 nM. |
|
| DC21870 |
BPR1J373 |
BPR1J373 is a potent, orally available multitargeted kinase inhibitor, potently inhibits FLT3, c-KIT, VEGFR1-3, Aurora A, PDGFRα, PDGFRβ, RET, and SRC with IC50 values of <100 nM. |
|
| DC20825 |
BPR1K653 |
BPR1K653 is a novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively. |
|
| DC7951 |
Glutaminase Inhibitor II, BPTES
Featured
|
BPTES is a selective inhibitor of Glutaminase GLS1 (KGA) |
|
